Managing Expectations: "We're Still On Target" Says AstraZeneca CEO
Pascal Soriot says AstraZeneca remains on track to hit its $45bn sales target in 2023 – more or less - but to do that the UK's second biggest drug maker must maintain recent improvements in R&D productivity.
You may also be interested in...
AstraZeneca agreed two new deals with Chinese tech groups Alibaba and Tencent as it tries to expand business in modernizing China, now the UK drug maker's second-largest market after the US.
Evotec’s multimodality approach to drug discovery landed the biotech two new discovery collaborations this week, underscoring its emphasis on patient-driven data.
Novo Nordisk and Evotec will identify and develop novel drugs for treating chronic kidney disease, using datasets of CKD patients provided by the Danish group and from other sources.